简约宿主炎症生物标志物特征可预测晚期HIV患者的突发结核与死亡
REMEMBER随机临床试验纳入850例CD4<50 cells/µL的晚期HIV患者,比较经验性抗结核治疗与异烟肼预防治疗。病例队列研究(n=257)发现6种生物标志物组合(CXCL10、IL-1β、IL-10、sCD14、TNF-α、TNF-β)预测突发结核的敏感性0.90、特异性0.71、AUC 0.81。该特征或可用于分层选择需加强监测和新型干预的患者。
要点
- 6种炎症生物标志物组合预测晚期HIV患者突发结核的AUC为0.81。
- 与突发结核相关的标志物(IL-1β、IL-6)与死亡相关标志物有重叠。
- 突发结核者标志物水平随时间下降,死亡者持续升高。
核心结论
- 在晚期HIV患者中,简约炎症生物标志物特征可预测启动ART和结核预防治疗后仍发生结核的最高风险者。
- 该特征可能是有前景的分层工具,用于选择可从加强监测和新型干预中获益的患者。
研究设计与样本
- REMEMBER随机临床试验纳入850例启动ART的HIV患者(CD4<50 cells/µL),随机接受经验性抗结核治疗或异烟肼预防治疗。
- 开展按国家和治疗组分层的病例队列研究(n=257),病例定义为ART启动后48周内突发结核或全因死亡。
- 使用多重免疫检测面板和ELISA评估血浆中26种生物标志物。
主要发现
- 850例中52例(6.1%)发生结核,47例(5.5%)死亡,其中13例死亡前有结核。
- 与突发结核相关的生物标志物(IL-1β、IL-6)与死亡相关标志物重叠。
- 突发结核者生物标志物水平随时间下降,死亡者持续升高。
- 最终6种生物标志物模型(CXCL10、IL-1β、IL-10、sCD14、TNF-α、TNF-β)预测突发结核的敏感性0.90(95%CI:.87-.94),特异性0.71(95%CI:.68-.75),AUC 0.81(95%CI:.78-.83)。
临床怎么用
- 该生物标志物特征可用于识别晚期HIV患者中启动ART和结核预防治疗后仍高风险的结核或死亡人群。
- 高风险患者可能适合加强监测和新型干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with advanced human immunodeficiency virus (HIV) (CD4 < 50) remain at high risk of tuberculosis (TB) or death despite the initiation of antiretroviral therapy (ART). We aimed to identify immunological profiles that were most predictive of incident TB disease and death. METHODS: The REMEMBER randomized clinical trial enrolled 850 participants with HIV (CD4 < 50 cells/µL) at ART initiation to receive either empiric TB treatment or isoniazid preventive therapy (IPT). A case-cohort study (n = 257) stratified by country and treatment arm was performed. Cases were defined as incident TB or all-cause death within 48 weeks after ART initiation. Using multiplexed immunoassay panels and ELISA, 26 biomarkers were assessed in plasma. RESULTS: In total, 52 (6.1%) of 850 participants developed TB; 47 (5.5%) died (13 of whom had antecedent TB). Biomarkers associated with incident TB overlapped with those associated with death (interleukin [IL]-1β, IL-6). Biomarker levels declined over time in individuals with incident TB while remaining persistently elevated in those who died. Dividing the cohort into development and validation sets, the final model of 6 biomarkers (CXCL10, IL-1β, IL-10, sCD14, tumor necrosis factor [TNF]-α, and TNF-β) achieved a sensitivity of 0.90 (95% confidence interval [CI]: .87-.94) and a specificity of 0.71(95% CI: .68-.75) with an area under the curve (AUC) of 0.81 (95% CI: .78-.83) for incident TB. CONCLUSION: Among people with advanced HIV, a parsimonious inflammatory biomarker signature predicted those at highest risk for developing TB despite initiation of ART and TB preventive therapies. The signature may be a promising stratification tool to select patients who may benefit from increased monitoring and novel interventions. CLINICAL TRIALS REGISTRATION: NCT01380080.
引用
- Manabe YC, Andrade BB, Gupte N, et al. A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus. Clin Infect Dis. 2020. PMID: 31761933. doi:10.1093/cid/ciz1147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。